CytomX Therapeutics (NASDAQ:CTMX) Sets New 12-Month High on Analyst Upgrade

CytomX Therapeutics, Inc. (NASDAQ:CTMX)’s share price hit a new 52-week high during mid-day trading on Monday after Wedbush raised their price target on the stock from $6.00 to $11.00. Wedbush currently has an outperform rating on the stock. CytomX Therapeutics traded as high as $7.74 and last traded at $7.28, with a volume of 57367736 shares. The stock had previously closed at $4.68.

A number of other research firms have also recently issued reports on CTMX. Oppenheimer reiterated an “outperform” rating and issued a $12.00 target price on shares of CytomX Therapeutics in a research note on Monday. Barclays increased their price target on CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Guggenheim reiterated a “buy” rating and issued a $10.00 price objective on shares of CytomX Therapeutics in a research report on Monday, March 9th. Piper Sandler boosted their price objective on CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Finally, Cantor Fitzgerald increased their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, CytomX Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Key CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 Varseta‑M expansion showed meaningful activity in heavily pretreated metastatic colorectal cancer (32% response rate at 10 mg/kg Q3W; estimated PFS ~7.1 months) with a manageable safety profile and planned FDA discussions to align on potential registrational trial — this is the primary catalyst for the earlier rally. Read More.
• Positive Sentiment: Multiple firms upgraded or raised price targets after the data (examples: Wedbush, HC Wainwright, JPMorgan noted higher PTs and upgraded ratings), which amplified buying interest and momentum. Read More.
• Neutral Sentiment: Company released its Q4 materials, slide deck and hosted an earnings call discussing the clinical progress and next‑steps (including combination studies and timelines) — useful context for longer‑term investors assessing pathway to a registrational study. Read More.
• Negative Sentiment: CytomX filed for an underwritten public offering to raise $250M (common stock and pre‑funded warrants) — a near‑term dilution risk that likely pressured the stock after the initial data‑driven surge. Read More.
• Negative Sentiment: Q4 results missed expectations (EPS and revenue; EPS -$0.22 vs. est. -$0.08; revenue ~$0.66M vs. est. ~$7.33M), which reinforces near‑term funding needs and contributed to selling pressure. Read More.

Institutional Trading of CytomX Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. bought a new stake in shares of CytomX Therapeutics during the 1st quarter valued at $39,000. Woodline Partners LP bought a new position in shares of CytomX Therapeutics in the 1st quarter worth $1,054,000. Geode Capital Management LLC grew its stake in shares of CytomX Therapeutics by 103.4% during the second quarter. Geode Capital Management LLC now owns 1,745,176 shares of the biotechnology company’s stock worth $3,963,000 after purchasing an additional 887,218 shares during the period. Franklin Resources Inc. acquired a new stake in shares of CytomX Therapeutics during the second quarter worth $13,096,000. Finally, XTX Topco Ltd bought a new stake in CytomX Therapeutics in the second quarter valued at about $277,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Stock Down 19.3%

The business has a fifty day moving average of $5.26 and a 200 day moving average of $4.09. The firm has a market cap of $923.39 million, a P/E ratio of -136.25 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The company had revenue of $0.66 million for the quarter, compared to the consensus estimate of $7.33 million. CytomX Therapeutics had a negative return on equity of 20.65% and a negative net margin of 22.79%. On average, sell-side analysts expect that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.